

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) An isolated antigen polypeptide consisting of residues 600-1,960 of SEQ ID NO: 17.

2.-11. (Canceled)

12. (Withdrawn – Currently Amended) A ligand which recognizes the antigen polypeptide according to claim 1.

13. (Withdrawn) The ligand according to claim 12, which is an antibody.

14. (Withdrawn) The ligand according to claim 12, which is a monoclonal antibody.

15. (Withdrawn) The ligand according to claim 12, wherein the monoclonal antibody is a human monoclonal antibody.

16. (Withdrawn) The ligand according to claim 12, which is a cancer reactive monoclonal antibody.

17. (Withdrawn) The ligand according to claim 16, wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.

18. (Withdrawn) The ligand according to claim 12, wherein a heavy chain hypervariable region comprises the amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light chain hypervariable region comprises the amino acid sequences of SEQ ID NOs: 4, 5 and 6.

19. (Withdrawn) The ligand according to claim 12, which comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 8.

20. (Withdrawn) A pharmaceutical composition, which comprises the ligand according to claim 12 and a pharmaceutically acceptable carrier.

21. (Withdrawn) The pharmaceutical composition according to claim 20, which is a targeting therapy agent.

22. (Withdrawn) The pharmaceutical composition according to claim 20, which targets at a cancer tissue or a cancer cell.

23. (Withdrawn) The pharmaceutical composition according to claim 20, which comprises an antitumor agent, an antitumor protein, an enzyme, a gene or an isotope for treatment.

24. (Withdrawn) The pharmaceutical composition according to claim 20, which is an antitumor agent.

25. (Withdrawn) The pharmaceutical composition according to claim 20, wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.

26. (Withdrawn) The pharmaceutical composition according to claim 20, which comprises liposome.

27. (Withdrawn) A composition, which comprises the ligand according to claim 12 and a labeling agent.

28. (Withdrawn) The composition according to claim 27, which specifically labels a cancer tissue or a cancer cell.

29. (Withdrawn) The composition according to claim 27, wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.

30. (Withdrawn) The composition according to claim 27, wherein the labeling agent is a fluorescent, an enzyme, an isotope or an MRI contrast medium.

31. (Withdrawn – Currently Amended) A method for treating a cancer disease of a cancer disease patient, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to claim 20 to treat the cancer disease of the cancer disease patient,

wherein the cancer disease patient expresses an antigen a polypeptide consisting of residues 600-1,960 of SEQ ID NO: 17.

32. (Withdrawn – Currently Amended) A method for treating a cancer disease of a cancer disease patient, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to claim 20 to treat the cancer disease of the cancer disease patient,

wherein the cancer disease patient has a cell which can be labeled by a composition comprising (a) a ligand which recognizes ~~an antigen~~ a polypeptide consisting of residues 600-1,960 of SEQ ID NO: 17, and (b) a labeling agent.

33. (Withdrawn – Currently Amended) The ligand according to claim 12, wherein the binding activity of the ligand which recognizes ~~an antigen~~ a polypeptide consisting of residues 600-1,960 of SEQ ID NO: 17 to the ~~antigen~~ polypeptide is from  $0.5 \times 10^6$  units/mg to  $2.0 \times 10^6$  units/mg.

34. (Withdrawn) The ligand according to claim 12, wherein the binding activity is from  $0.7 \times 10^6$  units/mg to  $1.5 \times 10^6$  units/mg, from  $0.7 \times 10^6$  units/mg to  $1.3 \times 10^6$  units/mg, or from  $0.8 \times 10^6$  units/mg to  $1.2 \times 10^6$  units/mg.

35. (Withdrawn) The ligand according to claim 12, wherein the binding activity is from  $0.8 \times 10^6$  units/mg to  $1.2 \times 10^6$  units/mg.

36.-41. (Canceled)

42. (Withdrawn) A method for treating a cancer disease of a cancer disease patient, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to claim 20 to treat the cancer disease of the cancer disease patient.